{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:02:38Z","timestamp":1770886958995,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404191"],"award-info":[{"award-number":["82404191"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hubei Provincial Key Research and Development Program","award":["2024BCB008"],"award-info":[{"award-number":["2024BCB008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01382-4","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:06:52Z","timestamp":1770880012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Systemic Therapy for Metastatic Pancreatic Neuroendocrine Neoplasms"],"prefix":"10.1007","volume":"27","author":[{"given":"Minxiao","family":"Yi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"1382_CR1","first-page":"471","volume":"68","author":"M Cives","year":"2018","unstructured":"Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68:471\u201387.","journal-title":"CA Cancer J Clin"},{"key":"1382_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature21063","volume":"543","author":"A Scarpa","year":"2017","unstructured":"Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543:65\u201371.","journal-title":"Nature"},{"key":"1382_CR3","doi-asserted-by":"crossref","unstructured":"Kaelin WG. Jr. Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. J Clin Invest. 2022;132:1\u20139.","DOI":"10.1172\/JCI162480"},{"key":"1382_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/annonc\/mds276","volume":"24","author":"H Sorbye","year":"2013","unstructured":"Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced Gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24:152\u201360.","journal-title":"Ann Oncol"},{"key":"1382_CR5","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/JCO.23.01529","volume":"41","author":"J Del Rivero","year":"2023","unstructured":"Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, et al. Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. J Clin Oncol. 2023;41:5049\u201367.","journal-title":"J Clin Oncol"},{"key":"1382_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1210\/endrev\/bnad006","volume":"44","author":"R Garcia-Carbonero","year":"2023","unstructured":"Garcia-Carbonero R, Anton-Pascual B, Modrego A, Del Carmen Riesco-Martinez M, Lens-Pardo A, Carretero-Puche C, et al. Advances in the treatment of gastroenteropancreatic neuroendocrine carcinomas: are we moving forward? Endocr Rev. 2023;44:724\u201336.","journal-title":"Endocr Rev"},{"key":"1382_CR7","doi-asserted-by":"crossref","unstructured":"Cordero-Hernandez IS, Ross AC, Dasari A, Halperin DM, Chasen B, Yao JC. Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024;31:1\u20137.","DOI":"10.1530\/ERC-23-0203"},{"key":"1382_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11864-019-0690-x","volume":"20","author":"H Hauser","year":"2019","unstructured":"Hauser H, Gerson DS, Reidy-Lagunes D, Raj N. Systemic therapies for metastatic pancreatic neuroendocrine tumors. Curr Treat Options Oncol. 2019;20:87.","journal-title":"Curr Treat Options Oncol"},{"key":"1382_CR9","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27:4656\u201363.","journal-title":"J Clin Oncol"},{"key":"1382_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, Phan AT, Raderer M, Sedl\u00e1\u010dkov\u00e1 E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224\u201333.","journal-title":"N Engl J Med"},{"key":"1382_CR11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s12020-020-02475-2","volume":"71","author":"ME Caplin","year":"2021","unstructured":"Caplin ME, Pavel M, Phan AT, \u0106wik\u0142a JB, Sedl\u00e1\u010dkov\u00e1 E, Thanh XT, et al. Lanreotide autogel\/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021;71:502\u201313.","journal-title":"Endocrine"},{"key":"1382_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2022.07.033","volume":"175","author":"C Lepage","year":"2022","unstructured":"Lepage C, Phelip JM, Lievre A, Le-Malicot K, Dahan L, Tougeron D, et al. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: an international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: an FFCD study. Eur J Cancer. 2022;175:31\u201340.","journal-title":"Eur J Cancer"},{"key":"1382_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ejca.2021.06.056","volume":"157","author":"M Pavel","year":"2021","unstructured":"Pavel M, \u0106wik\u0142a JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, et al. Efficacy and safety of high-dose Lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur J Cancer. 2021;157:403\u201314.","journal-title":"Eur J Cancer"},{"key":"1382_CR14","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2013dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317.","journal-title":"Lancet"},{"key":"1382_CR15","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-Term Efficacy, Survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617\u201324.","journal-title":"Clin Cancer Res"},{"key":"1382_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514\u201323.","journal-title":"N Engl J Med"},{"key":"1382_CR17","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844\u201360.","journal-title":"Ann Oncol"},{"key":"1382_CR18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/MPA.0000000000000762","volume":"46","author":"F Panzuto","year":"2017","unstructured":"Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T, Campana D, et al. Everolimus in pancreatic neuroendocrine carcinomas G3. Pancreas. 2017;46:302\u20135.","journal-title":"Pancreas"},{"key":"1382_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nrd2380","volume":"6","author":"S Faivre","year":"2007","unstructured":"Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for Sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007;6:734\u201345.","journal-title":"Nat Rev Drug Discov"},{"key":"1382_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/annonc\/mdw561","volume":"28","author":"S Faivre","year":"2017","unstructured":"Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol. 2017;28:339\u201343.","journal-title":"Ann Oncol"},{"key":"1382_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000487237","volume":"107","author":"A Pellat","year":"2018","unstructured":"Pellat A, Dreyer C, Couffignal C, Walter T, Lombard-Bohas C, Niccoli P, et al. Clinical and biomarker evaluations of Sunitinib in patients with grade 3 digestive neuroendocrine neoplasms. Neuroendocrinology. 2018;107:24\u201331.","journal-title":"Neuroendocrinology"},{"key":"1382_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa2403991","volume":"392","author":"JA Chan","year":"2025","unstructured":"Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, et al. Phase 3 trial of Cabozantinib to treat advanced neuroendocrine tumors. N Engl J Med. 2025;392:653\u201365.","journal-title":"N Engl J Med"},{"key":"1382_CR23","doi-asserted-by":"publisher","first-page":"S752","DOI":"10.1016\/j.annonc.2024.08.1205","volume":"35","author":"A Koenig","year":"2024","unstructured":"Koenig A, Reinecke J, Halfen J, Lang K, K\u00f6nig U, Tostmann R, et al. 1146MO interim analysis of CABONEN: A multicenter phase II trial investigating Cabozantinib in patients with advanced, low proliferative NEN G3. Ann Oncol. 2024;35:S752.","journal-title":"Ann Oncol"},{"key":"1382_CR24","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu J, Shen L, Bai C, Wang W, Li J, Yu X, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:1489\u201399.","journal-title":"Lancet Oncol"},{"key":"1382_CR25","doi-asserted-by":"publisher","first-page":"100453","DOI":"10.1016\/j.esmoop.2022.100453","volume":"7","author":"J Li","year":"2022","unstructured":"Li J, Cheng Y, Bai C, Xu J, Shen L, Li J, et al. Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies. ESMO Open. 2022;7:100453.","journal-title":"ESMO Open"},{"key":"1382_CR26","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1200\/JCO.20.03368","volume":"39","author":"J Capdevila","year":"2021","unstructured":"Capdevila J, Fazio N, Lopez C, Teul\u00e9 A, Valle JW, Tafuto S, et al. Lenvatinib in patients with advanced grade 1\/2 pancreatic and Gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509). J Clin Oncol. 2021;39:2304\u201312.","journal-title":"J Clin Oncol"},{"key":"1382_CR27","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1200\/JCO.2019.37.4_suppl.332","volume":"37","author":"J Capdevila","year":"2019","unstructured":"Capdevila J, Fazio N, L\u00f3pez-L\u00f3pez C, Teule A, Valle JW, Tafuto S, et al. Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1\/G2 advanced pancreatic (panNETs) and Gastrointestinal (giNETs) neuroendocrine tumors (NETs): updated results from the phase II TALENT trial (GETNE 1509). J Clin Oncol. 2019;37:332.","journal-title":"J Clin Oncol"},{"key":"1382_CR28","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/bjc.2013.470","volume":"109","author":"HK Ahn","year":"2013","unstructured":"Ahn HK, Choi JY, Kim KM, Kim H, Choi SH, Park SH, et al. Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. Br J Cancer. 2013;109:1414\u20139.","journal-title":"Br J Cancer"},{"key":"1382_CR29","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/annonc\/mdv252","volume":"26","author":"E Grande","year":"2015","unstructured":"Grande E, Capdevila J, Castellano D, Teul\u00e9 A, Dur\u00e1n I, Fuster J, et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish task force group for neuroendocrine tumors (GETNE). Ann Oncol. 2015;26:1987\u201393.","journal-title":"Ann Oncol"},{"key":"1382_CR30","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/MPA.0000000000001950","volume":"50","author":"M Zhu","year":"2021","unstructured":"Zhu M, Costello BA, Yin J, Pettinger AM, Strosberg JR, Erlichman C, et al. Phase II trial of bevacizumab monotherapy in pancreatic neuroendocrine tumors. Pancreas. 2021;50:1435\u20139.","journal-title":"Pancreas"},{"key":"1382_CR31","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(25)00099-3","volume":"26","author":"R Srinivasan","year":"2025","unstructured":"Srinivasan R, Iliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, et al. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol. 2025;26:571\u201382.","journal-title":"Lancet Oncol"},{"key":"1382_CR32","first-page":"1285","volume":"20","author":"E Pelle","year":"2022","unstructured":"Pelle E, Al-Toubah T, Morse B, Strosberg J. Belzutifan in a patient with VHL-Associated metastatic pancreatic neuroendocrine tumor. J Natl Compr Canc Netw. 2022;20:1285\u20137.","journal-title":"J Natl Compr Canc Netw"},{"key":"1382_CR33","doi-asserted-by":"publisher","first-page":"S1008","DOI":"10.1016\/j.annonc.2025.08.2338","volume":"36","author":"J Capdevila","year":"2025","unstructured":"Capdevila J, Artamonova E, de Jesus Acosta A, Niccoli P, Toth M, Ramirez RA, et al. Belzutifan for advanced pancreatic neuroendocrine tumors (panNETs): results from cohort A2 of the phase II LITESPARK-015 study. Ann Oncol. 2025;36:S1008\u20139.","journal-title":"Ann Oncol"},{"key":"1382_CR34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/JCO.22.01013","volume":"41","author":"PL Kunz","year":"2023","unstructured":"Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, et al. Randomized study of Temozolomide or Temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023;41:1359\u201369.","journal-title":"J Clin Oncol"},{"key":"1382_CR35","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/onco.13923","volume":"26","author":"DL Chan","year":"2021","unstructured":"Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, et al. Temozolomide in grade 3 gastroenteropancreatic neuroendocrine neoplasms: A multicenter retrospective review. Oncologist. 2021;26:950\u20135.","journal-title":"Oncologist"},{"key":"1382_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.6004\/jnccn.2021.7017","volume":"20","author":"T Al-Toubah","year":"2021","unstructured":"Al-Toubah T, Pelle E, Valone T, Haider M, Strosberg JR. Efficacy and toxicity analysis of capecitabine and Temozolomide in neuroendocrine neoplasms. J Natl Compr Canc Netw. 2021;20:29\u201336.","journal-title":"J Natl Compr Canc Netw"},{"key":"1382_CR37","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1159\/000510159","volume":"111","author":"W Wang","year":"2021","unstructured":"Wang W, Zhang Y, Peng Y, Jin KZ, Li YL, Liang Y, et al. A Ki-67 index to predict treatment response to the Capecitabine\/Temozolomide regimen in neuroendocrine neoplasms: A retrospective multicenter study. Neuroendocrinology. 2021;111:752\u201363.","journal-title":"Neuroendocrinology"},{"key":"1382_CR38","doi-asserted-by":"publisher","first-page":"101667","DOI":"10.1016\/j.eclinm.2022.101667","volume":"54","author":"Y Chi","year":"2022","unstructured":"Chi Y, Song L, Liu W, Zhou Y, Miao Y, Fang W, et al. S-1\/temozolomide versus S-1\/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial. EClinicalMedicine. 2022;54:101667.","journal-title":"EClinicalMedicine"},{"key":"1382_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12020-021-02859-y","volume":"75","author":"H Lahner","year":"2022","unstructured":"Lahner H, Mathew A, Klocker AL, Unger N, Theysohn J, Rekowski J, et al. Streptozocin\/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. Endocrine. 2022;75:293\u2013302.","journal-title":"Endocrine"},{"key":"1382_CR40","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/jamaoncol.2022.3395","volume":"8","author":"C Morizane","year":"2022","unstructured":"Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, et al. Effectiveness of Etoposide and cisplatin vs Irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol. 2022;8:1447\u201355.","journal-title":"JAMA Oncol"},{"key":"1382_CR41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/onco.13611","volume":"26","author":"T Al-Toubah","year":"2021","unstructured":"Al-Toubah T, Morse B, Pelle E, Strosberg J. Efficacy of FOLFOX in patients with aggressive pancreatic neuroendocrine tumors after prior Capecitabine\/Temozolomide. Oncologist. 2021;26:115\u20139.","journal-title":"Oncologist"},{"key":"1382_CR42","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1159\/000518650","volume":"112","author":"P Girot","year":"2022","unstructured":"Girot P, Baudin E, Senellart H, Bouarioua N, Hentic O, Guimbaud R, et al. Oxaliplatin and 5-Fluorouracil in advanced Well-Differentiated digestive neuroendocrine tumors: A multicenter National retrospective study from the French group of endocrine tumors. Neuroendocrinology. 2022;112:537\u201346.","journal-title":"Neuroendocrinology"},{"key":"1382_CR43","doi-asserted-by":"publisher","first-page":"e247005","DOI":"10.6004\/jnccn.2024.7005","volume":"22","author":"M Borghesani","year":"2024","unstructured":"Borghesani M, Reni A, Lauricella E, Rossi A, Moscarda V, Trevisani E, et al. Efficacy and toxicity analysis of mFOLFIRINOX in High-Grade gastroenteropancreatic neuroendocrine neoplasms. J Natl Compr Canc Netw. 2024;22:e247005.","journal-title":"J Natl Compr Canc Netw"},{"key":"1382_CR44","doi-asserted-by":"crossref","unstructured":"Apostolidis L, Dal Buono A, Merola E, Jann H, J\u00e4ger D, Wiedenmann B et al. Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3). Cancers (Basel). 2021;13:1\u201314.","DOI":"10.3390\/cancers13081936"},{"key":"1382_CR45","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","volume":"22","author":"M Ambrosini","year":"2025","unstructured":"Ambrosini M, Manca P, Nasca V, Sciortino C, Ghelardi F, Seligmann JF, et al. Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers. Nat Rev Clin Oncol. 2025;22:385\u2013407.","journal-title":"Nat Rev Clin Oncol"},{"key":"1382_CR46","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365.","journal-title":"Lancet Oncol"},{"key":"1382_CR47","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1158\/1078-0432.CCR-19-4000","volume":"26","author":"M Lu","year":"2020","unstructured":"Lu M, Zhang P, Zhang Y, Li Z, Gong J, Li J, et al. Efficacy, Safety, and biomarkers of Toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: A Multiple-Center phase Ib trial. Clin Cancer Res. 2020;26:2337\u201345.","journal-title":"Clin Cancer Res"},{"key":"1382_CR48","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1002\/cncr.33591","volume":"127","author":"SP Patel","year":"2021","unstructured":"Patel SP, Mayerson E, Chae YK, Strosberg J, Wang J, Konda B, et al. A phase II basket trial of dual Anti-CTLA-4 and Anti-PD-1 Blockade in rare tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. Cancer. 2021;127:3194\u2013201.","journal-title":"Cancer"},{"key":"1382_CR49","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1158\/1078-0432.CCR-20-0621","volume":"26","author":"O Klein","year":"2020","unstructured":"Klein O, Kee D, Markman B, Michael M, Underhill C, Carlino MS, et al. Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: A subgroup analysis of the CA209-538 clinical trial for rare cancers. Clin Cancer Res. 2020;26:4454\u20139.","journal-title":"Clin Cancer Res"},{"key":"1382_CR50","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1038\/s41467-023-38611-5","volume":"14","author":"J Capdevila","year":"2023","unstructured":"Capdevila J, Hernando J, Teule A, Lopez C, Garcia-Carbonero R, Benavent M, et al. Durvalumab plus Tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin. Nat Commun. 2023;14:2973.","journal-title":"Nat Commun"},{"key":"1382_CR51","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1200\/JCO.2024.42.16_suppl.4010","volume":"42","author":"M Lu","year":"2024","unstructured":"Lu M, Zhang P, Luo S, Chen J, Yang J, Song Z, et al. A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I\/II, first-in-human, open-label, multicenter, dose escalation\/expansion study. J Clin Oncol. 2024;42:4010.","journal-title":"J Clin Oncol"},{"key":"1382_CR52","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s12022-020-09657-8","volume":"32","author":"C Liverani","year":"2021","unstructured":"Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, et al. Diagnostic and predictive role of DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms. Endocr Pathol. 2021;32:309\u201317.","journal-title":"Endocr Pathol"},{"key":"1382_CR53","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1158\/1535-7163.MCT-23-0524","volume":"23","author":"ME Molloy","year":"2024","unstructured":"Molloy ME, Aaron WH, Barath M, Bush MC, Callihan EC, Carlin K, et al. HPN328, a trispecific T Cell-Activating protein construct targeting DLL3-Expressing solid tumors. Mol Cancer Ther. 2024;23:1294\u2013304.","journal-title":"Mol Cancer Ther"},{"key":"1382_CR54","doi-asserted-by":"publisher","first-page":"8090","DOI":"10.1200\/JCO.2024.42.16_suppl.8090","volume":"42","author":"H Beltran","year":"2024","unstructured":"Beltran H, Johnson ML, Jain P, Schenk EL, Sanborn RE, Thompson JR, et al. Updated results from a phase 1\/2 study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC). J Clin Oncol. 2024;42:8090.","journal-title":"J Clin Oncol"},{"key":"1382_CR55","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO-25-00363","volume":"43","author":"M Wermke","year":"2025","unstructured":"Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed MF, Alese OB, et al. Phase I Dose-Escalation results for the Delta-Like ligand 3\/CD3 IgG-Like T-Cell engager Obrixtamig (BI 764532) in patients with Delta-Like ligand 3\u2009+\u2009Small cell lung cancer or neuroendocrine carcinomas. J Clin Oncol. 2025;43:3021\u201331.","journal-title":"J Clin Oncol"},{"key":"1382_CR56","doi-asserted-by":"publisher","first-page":"103022","DOI":"10.1016\/j.ctrv.2025.103022","volume":"140","author":"M Alameda-Guijarro","year":"2025","unstructured":"Alameda-Guijarro M, Rueda-Lara A, Martin-Montalvo G, Higuera O, Guti\u00e9rrez-Sainz L, Jim\u00e9nez-Bou D, et al. Novel therapies targeting delta-like ligand 3 (DLL3) in pulmonary and gastroenteropancreatic neuroendocrine carcinomas. Cancer Treat Rev. 2025;140:103022.","journal-title":"Cancer Treat Rev"},{"key":"1382_CR57","doi-asserted-by":"publisher","first-page":"S1412","DOI":"10.1016\/j.annonc.2022.08.044","volume":"33","author":"R Salazar","year":"2022","unstructured":"Salazar R, Tafuto S, Krogh M, Teule A, Garcia-Carbonero R, Klumpen H, et al. LBA45 randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive pannets: the SEQTOR study (GETNE 1206). Ann Oncol. 2022;33:S1412.","journal-title":"Ann Oncol"},{"key":"1382_CR58","doi-asserted-by":"publisher","unstructured":"Capdevila J, Amthauer H, Ansquer C, Deshayes E, Garcia-Carbonero R, Teule A et al. Efficacy, safety and subgroup analysis of 177Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: Phase III COMPETE trial. Annals of Oncology. 2025; 36 (suppl_2): S1016-S1033. https:\/\/doi.org\/10.1016\/annonc\/annonc1926.","DOI":"10.1016\/annonc\/annonc"},{"key":"1382_CR59","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1470-2045(15)70136-1","volume":"16","author":"AT Phan","year":"2015","unstructured":"Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, et al. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015;16:695\u2013703.","journal-title":"Lancet Oncol"},{"key":"1382_CR60","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1200\/JCO.2025.43.4_suppl.652","volume":"43","author":"S Hijioka","year":"2025","unstructured":"Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T, Boku N, et al. A phase III study of combination therapy with everolimus plus Lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET). J Clin Oncol. 2025;43:652.","journal-title":"J Clin Oncol"},{"key":"1382_CR61","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1038\/s41416-023-02462-0","volume":"129","author":"S Morken","year":"2023","unstructured":"Morken S, Langer SW, Sundl\u00f6v A, Vestermark LW, Ladekarl M, Hjortland GO, et al. Phase II study of everolimus and Temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms. Br J Cancer. 2023;129:1930\u20139.","journal-title":"Br J Cancer"},{"key":"1382_CR62","doi-asserted-by":"publisher","first-page":"e13227","DOI":"10.1111\/jne.13227","volume":"35","author":"C Lacombe","year":"2023","unstructured":"Lacombe C, Perrier M, Hentic O, Brixi H, De Rycke O, Cros J, et al. FOLFOX-bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors. J Neuroendocrinol. 2023;35:e13227.","journal-title":"J Neuroendocrinol"},{"key":"1382_CR63","doi-asserted-by":"crossref","unstructured":"Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9:1\u201313.","DOI":"10.1126\/scitranslmed.aak9679"},{"key":"1382_CR64","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1001\/jamaoncol.2022.0212","volume":"8","author":"DM Halperin","year":"2022","unstructured":"Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, et al. Assessment of clinical response following Atezolizumab and bevacizumab treatment in patients with neuroendocrine tumors: A nonrandomized clinical trial. JAMA Oncol. 2022;8:904\u20139.","journal-title":"JAMA Oncol"},{"key":"1382_CR65","doi-asserted-by":"publisher","first-page":"113539","DOI":"10.1016\/j.ejca.2024.113539","volume":"199","author":"P Zhang","year":"2024","unstructured":"Zhang P, Shi S, Xu J, Chen Z, Song L, Zhang X, et al. Surufatinib plus Toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: an open-label, single-arm, multi-cohort phase II trial. Eur J Cancer. 2024;199:113539.","journal-title":"Eur J Cancer"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01382-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01382-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01382-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:03:27Z","timestamp":1770883407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01382-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1382"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01382-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"10"}}